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Abstract:  The discovery of endothelin created a lot of enthusiasm and paved new therapeutic avenues for the treatment 
of arterial hypertension. Endothelin plays a significant role in blood pressure regulation through pronounced vasoconstric-
tion and modulation of sodium and water reabsorption in the kidneys. Endothelin receptor antagonists have been tested in 
many clinical trials in patients with arterial hypertension, heart failure, pulmonary arterial hypertension, systemic sclero-
sis, chronic kidney disease, and diabetic nephropathy. However, the results were usually disappointing, except in pulmo-
nary hypertension and scleroderma digital ulcers. The future of ERAs for the treatment of arterial hypertension and 
chronic kidney disease does not seem bright, and only the combination with other classes of antihypertensive drugs might 
offer a way out. 
Keywords: Endothelin, endothelin receptor antagonists, hypertension, chronic kidney disease, heart failure, pulmonary hyper-
tension, pre-eclampsia, antineoplastic agents. 
INTRODUCTION 
The role of endothelial cells in the regulation of vascular 
tone and blood pressure homeostasis attracted wide scientific 
interest during the last three decades. Furchgott was the first 
to report in 1980 that acetylcholine-induced relaxation of 
vascular smooth muscle cells is mediated by the endothelium 
[1], and some years later himself and Ignarro identified nitric 
oxide (NO) as the endothelial mediator [2, 3]. The simulta-
neous discovery of prostacyclin by Vane and Moncada in 
1982 [4] oriented cardiovascular physiological and pharma-
cological research towards the vasorelaxing properties of the 
vascular endothelium. However, endothelium-dependent 
vasoconstriction during anoxia was reported by Vanhoutte at 
about the same time [5], and an endotherium-derived con-
stricting factor was characterized from cultured endothelial 
cells by Hickey [6]. The isolation of endothelin by Yanagi-
sawa in 1988 [7] created a lot of enthusiasm and generated 
great expectations for the effective management of arterial 
hypertension.  
ENDOTHELINS AND ITS RECEPTORS 
Endothelins comprise a group of three peptides (ET-1, 
ET-2, and ET-3) with potent vasoconstrictive properties. The 
chemical structure of endothelins resembles the structure of 
sarafotoxins, which are venom neurotoxins produced in 
abundance in scorpions and snakes from the Atractaspis ge-
nus [8, 9]. Shortly after the discovery of endothelins, two 
subtypes of endothelin receptors were identified: ETA and 
ETB [10, 11]. 
 
 
*Address correspondence to this author at the 49 Konstantinoupoleos street, 
Hippokration Hospital, 54643 Thessaloniki, Greece; Tel: +30 2310992836; 
Fax: +30 2310992834; E-mail: michalisdoumas@yahoo.co.uk 
Endothelin-1 (ET-1) is produced by prepro-ET-1. Prepro-
ET-1 is cleaved to big ET-1, which in turn is being catalyzed 
to ET-1 by the endothelin-converting enzyme (ECE). ET-1 
predominates in vivo and is considered among the most po-
tent vasoconstrictive agents in nature. ET-1 results in strong 
and sustained vasoconstriction through activation of ETA 
receptors, while the activation of ETB receptors causes 
vasorelaxation via formation of NO [12]. 
ENDOTHELIN RECEPTOR ANTAGONISTS (ERAS) 
A quest for the discovery of effective and safe endothelin 
blockers resulted in the first compound at 1991 [13], only 3 
years after the isolation of ET-1 and one year after the identi-
fication of its receptors. The first clinical trial was published 
in 1995 by the recently deceased Prof. Kiowski in patients 
with heart failure [14]. Shortly thereafter several endothelin 
receptor antagonists have been discovered, which were either 
selective ETA or ETB antagonists or mixed ETA/ETB antago-
nists. 
It is therefore obvious that pharmaceutical advances pre-
ceded the physiological and pathophysiological research, 
before uncovering the role of endothelin in health and vari-
ous disease conditions. It is thus not surprising that the ma-
jority of clinical trials were either neutral or negative. Cur-
rently only two endothelin antagonists are approved for 
clinical use: bosentan (a mixed ETA and ETB antagonist) and 
ambrisentan (a selective ETA antagonist). These are the only 
survivors of a drug class (the ‘sentans’) originally comprised 
by dozens of compounds. According to both European and 
American guidelines, ERAs are recommended as first line 
agents in patients with mild-to-moderate pulmonary hyper-
tension [15, 16]. ERAs are also indicated for the treatment of 
scleroderma digital ulcer. 
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However, the forthcoming end of most drug patents 
within this category combined with many negative trials in 
several disease conditions and the risk of severe adverse ef-
fects during long-term therapy, cast significant doubts about 
the future of ERAs in arterial hypertension and other disease 
conditions (chronic kidney disease, diabetic nephropathy, 
heart failure, autoimmunity, cancer), apart from pulmonary 
hypertension and scleroderma ulcers. 
Hepatotoxicity represents a major concern with ERAs, 
especially when sulphonamide is included in the chemical 
structure [17, 18]. Sitaxentan was withdrawn from the mar-
ket due to 4 cases of fatal hepatotoxicity [19]. Although fatal 
liver failure was not reported with other marketed ERAs 
(bosentan and ambrisentan) [19], it has to be noted that 
bosentan is associated with frequent liver enzyme elevations 
(up to 10%) [20, 21], while ambrisentan seems more safe 
[22, 23].  
ENDOTHELIN AND THE KIDNEYS 
ETA receptor activation, apart from vasoconstriction, 
promotes oxidative stress, inflammation, and proteinuria [24-
26]. In contrast, ETB receptor activation, apart from vasodila-
tation, inhibits sodium reabsorption in the renal collecting 
ducts [27]. ETB blockade causes salt-sensitive hypertension 
[28, 29], and collecting duct ET-1 or ETB knockout mice 
exhibit blood pressure elevation and sodium retention [30, 
31]. 
Therefore, ET-1 seems to have opposing effects on blood 
pressure regulation by acting either in the renal cortex (pro-
moting hypertension through ETA activation) or in the renal 
medulla (promoting hypotension through ETB activation. 
Another factor that has to be considered is the sexual dimor-
phism observed in the effects of ET-1 on the kidneys. Fe-
male animals seem to be protected by ETA-induced decrease 
in medullary blood flow observed in male animals [32], a 
factor that is implicated in angiotensin II-induced hyperten-
sion. This seems to explain why female animals are less sus-
ceptible in angiotensin II-induced hypertension [33]. 
ERAS IN CHRONIC KIDNEY DISEASE 
The renal effects of ET-1 through ETA receptor activation 
(promotion of hypertension, inflammation, oxidative stress, 
and proteinuria), render ETA receptor antagonism an attrac-
tive option for the treatment of chronic kidney disease. In-
deed, several trials have been performed in patients with 
renal disease using ERAs. 
Recent studies showed that selective ETA receptor an-
tagonism in hypertensive patients with chronic kidney dis-
ease results in reduction of blood pressure, proteinuria, arte-
rial stiffness, and serum uric acid [34-36].  
More data is available for the use of ERAs in diabetic 
nephropathy. It has been shown that selective ETA receptor 
antagonists lower urinary albumin excretion rate in patients 
with diabetic nephropathy already on RAS inhibition (ACE-
inhibitors or ARBs) [37]. Moreover, the pronounced antipro-
teinuric properties of ERAs were confirmed in the ASCEND 
(A Study of Cardiovascular Events iN Diabetes) study, a 
large trial with avosentan on top of RAS inhibitors in pa-
tients with diabetic nephropathy [38]. However, this trial was 
prematurely terminated after only 4 months of follow-up due 
to a significant excess in cardiovascular events (heart failure 
and death) in the avosentan group. It has to be noted how-
ever that avosentan was used in this study in higher doses 
(25-50 mg) than the ones required (5-10 mg) to reduce al-
buminuria [39]. Moreover, diuretics were not used to com-
pensate for fluid retention, caused by ERAs. 
Finally, observational studies show that bosentan (a 
mixed ERA) appears to be safe and effective in scleroderma 
patients with renal crisis [40], and is currently under evalua-
tion in an open prospective study for the treatment of 
scleroderma renal crisis. 
ERAS IN HEART FAILURE 
ET-1 is implicated in the pathogenesis of heart failure. 
The majority of studies with ERAs were conducted in pa-
tients with either chronic or acute heart failure. A pilot study 
of bosentan for 2 weeks in patients heart failure was very 
promising, with favourable effects on cardiac and pulmonary 
hemodynamics: reductions in pulmonary and mean arterial 
pressure together with reductions in pulmonary and vascular 
resistance by 10-30% were accompanied by increases in car-
diac index by 13% [14]. This study was followed by several 
studies with mixed (bosentan, enrasentan) or selective (da-
rusentan) ERAs in patients with chronic heart failure [41-
45]. However, all studies failed to prove any significant 
benefit; instead, a significant increase in adverse effects was 
observed [41-45]. Similar disappointing results were ob-
tained in acute heart failure by using intravenous tezosentan 
(a mixed ERA) in several clinical trials, which were charac-
terized by lack of any significant benefit and increased fre-
quency of adverse events [46-51]. 
ERAS IN ARTERIAL HYPERTENSION 
Bosentan was the first molecule to be evaluated in pa-
tients with mild to moderate hypertension. Bosentan at a 
dose of 1,000 mg twice daily resulted in blood pressure re-
duction (11/6 mmHg) that was comparable to enalapril at 20 
mg after 4 weeks of active therapy [52]. In addition, there 
was no reflex activation of the sympathetic or the renin-
angiotensin system with bosentan. In terms of safety, bosen-
tan was well tolerated, apart from a significant elevation of 
liver enzymes in some patients, which was asymptomatic 
and completely reversible upon bosentan withdrawal. 
Despite the favourable effects of bosentan on blood pres-
sure reduction, the risk of hepatotoxicity during life-long 
therapy for a disease like hypertension which is not acutely 
life-threatening, combined with the lack of superiority over 
existing antihypertensive drugs, the need for dosing twice 
daily, and most of all the significant vasorelaxation in the 
pulmonary vascular bed, moved the research towards the 
management of pulmonary hypertension, while the field of 
arterial hypertension was actually abandoned. 
Darusentan, a selective ETA receptor antagonist, was the 
only other ERA which was evaluated in a small clinical 
study of patients with moderate hypertension [53]. Darusen-
tan at 100 mg reduced significantly both systolic and dia-
stolic blood pressure (by 11 and 8 mmHg, respectively) after 
6 weeks of therapy, without any significant adverse effect or 
signs of liver toxicity. 
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Erectile dysfunction is frequently encountered in patients 
with arterial hypertension [54, 55]. Animal data suggests that 
ET-1 is implicated in the pathophysiology of erectile dys-
function [56]. The use of ERAs in animals with erectile dys-
function yielded conflicting results [57, 58]. The only avail-
able study in humans is small and failed to show any signifi-
cant improvement on erectile function with ERA [59]. 
ERAS IN RESISTANT HYPERTENSION 
 Data in both animals and humans point towards endo-
thelin activation in severe hypertension [60, 61]. This obser-
vation prompted the design of clinical studies to evaluate the 
effects of ERAs in resistant hypertension, a condition de-
fined as the inability to achieve blood pressure goals despite 
the optimal use of 3 antihypertensive drugs, including a diu-
retic [62]. Darusentan was tested in a small, randomized, 
placebo-controlled study in patients with resistant hyperten-
sion, and resulted in significant blood pressure reduction 
(11/6 mmHg) after 10 weeks of treatment, without any sig-
nificant adverse effects [63]. This exploratory, dose-ranging 
study was followed by a larger study in 379 patients with 
resistant hypertension, randomized to 3 doses of darusentan 
(50, 100, and 300 mg) or placebo. A substantial reduction of 
systolic and diastolic blood pressure (up to 18/11 mmHg) 
was observed after 14 weeks of treatment in the active group, 
which was significantly higher compared to placebo (9/5 
mmHg) [64]. Moving to the next step, a comparison study 
versus guanfacine was designed. Unexpectedly, office blood 
pressure at study end was not significantly different from 
placebo, and the study did not meet its primary endpoint. Of 
not, significant blood pressure differences favouring da-
rusentan were observed during the study (at time-points be-
fore the end of the study), and more importantly ambulatory 
blood pressure reduction (a more reliable index than office 
blood pressure reduction) was significantly greater with da-
rusentan [65]. However, Gilead has already announced the 
cessation of darusentan development based on office blood 
pressure measurements, despite the findings in ambulatory 
blood pressure and prior data.  
ERAS IN PRE-ECLAMPSIA 
 A central role of ET-1 in pre-eclampsia has been re-
cently suggested by experimental studies, in which ET-1 was 
identified as the final mediator inducing hypertension in re-
sponse to placental ischemia [66, 67]. However, the clinical 
utility of this observation is limited because ERAs are con-
tra-indicated in pregnancy due to teratogenecity [68]. Lim-
ited experimental data suggests that selective ETA receptor 
antagonists might not be teratogenic in late gestation [69,70], 
which however should be considered with great scepticism. 
ERAS IN ANTINEOPLASTIC DRUGS-INDUCED HY-
PERTENSION 
Modern antineoplastic drugs targeting angiogenesis result 
in blood pressure elevation and frequently induce hyperten-
sion [71-73]. A reduction in NO bioavailability has been 
proposed as the mediating mechanism, however recent data 
in animals [74] and humans [75] suggests that angiogenesis 
inhibition results in substantial increases of ET-1 levels. 
Even more, a recent study reveals that hypertension is medi-
ated by endothelin and not oxidative stress or NO [76]. Fur-
thermore, ERAs prevented the development of hypertension 
during angiogenesis inhibition in rats [74, 77]. Moreover, the 
potential anti-neoplastic properties of ERAs might be of ad-
ditional benefit in these patients [78, 79].  
ERAS IN PULMONARY ARTERIAL HYPERTEN-
SION 
Although an extensive description of ERAs in pulmonary 
arterial hypertension is beyond the scope of this review pa-
per, a short summary seems necessary. Based on promising 
findings in experimental studies, two clinical trials with 
bosentan were conducted in patients with moderate to severe 
pulmonary hypertension (idiopathic or scleroderma-
associated) [80, 81]. Both trials showed a significant im-
provement of symptoms and patients’ quality of life, leading 
to the approval of bosentan for the management of moderate 
to severe pulmonary hypertension in 2002. Further studies 
proved the efficacy and safety of bosentan in patients with 
mild pulmonary hypertension, or pulmonary hypertension 
caused by HIV or congenital heart disease [82-84]. Similar 
beneficial effects were observed with ambrisentan in two 
large clinical trials and one long-term open study [85, 86]. 
Several other ERAs are under evaluation for the treatment of 
pulmonary arterial hypertension.  
FUTURE DIRECTIONS  
In our opinion, the future of endothelin inhibition for the 
management of arterial hypertension and chronic kidney 
disease lies in combination therapy with other classes of an-
tihypertensive drugs.  
A triple inhibitor of ECE, ACE, and neutral endopepti-
dase has been recently developed (Cgs 35601); however its 
use was limited by an increased risk for angioedema [87]. A 
combination of ETA antagonists with angiotensin receptor 
blockers might be more promising than the combination with 
ACE-inhibitors in terms of safety, with similar antihyperten-
sive efficacy. Indeed, such a molecule has been formed 
(PS433540), combining the properties of irbesartan with 
BMS193884 (a selective ETA antagonist) [88]. This dual 
angiotensin-endothelin A receptor antagonist (DARA) is 
orally active and potent, with favourable pharmacokinetic 
properties [89,90]. The results of the first randomized, pla-
cebo-controlled study in 114 patients with ambulatory-
confirmed hypertension were reported in the 2008 meeting 
of the American Society of Hypertension [91]. DARA was 
found to be both effective and safe, with only one patient 
developing edema, while no liver toxicity was observed.  
Another very attractive combination is the one that com-
bines endothelin inhibition with neutral endopeptidase in-
hibitors. Animal data with such combinations point towards 
beneficial effects on albuminuria and cardiac remodelling 
[92,93]. In addition, this combination offers the potential 
benefit to overcome fluid retention, which frequently occurs 
with ERAs. 
CONCLUSIONS 
The discovery of endothelin generated great expectations 
for the management of arterial hypertension and other dis-
ease conditions characterized by vasoconstriction. The potent 
and long-lasting vasoconstriction induced by ET-1 (via ETA 
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activation) combined with the effects of ET-1 on renal han-
dling of sodium and water (via ETB activation) point towards 
a significant role of ET-1 in blood pressure regulation. Sev-
eral antagonists of endothelin receptors have been devel-
oped, either selective ETA antagonists or mixed ETA/ETB 
antagonists. The subsequent conduction of numerous clinical 
trials in patients with arterial hypertension, heart failure, 
chronic kidney disease, and diabetic nephropathy however 
has not fulfilled our expectations and disappointing results 
were obtained. Problems in study design and the incomplete 
understanding of endothelin physiology might explain the 
negative outcome of the studies. Currently, ERAs are ap-
proved only for the treatment of pulmonary hypertension and 
scleroderma digital ulcers. ERAs in monotherapy for the 
treatment of arterial hypertension and chronic kidney disease 
seem to have reached a dead end, and only the combination 
with other classes of antihypertensive drugs might offer a 
way out.  
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